DE602005019728D1 - Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat - Google Patents

Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat

Info

Publication number
DE602005019728D1
DE602005019728D1 DE602005019728T DE602005019728T DE602005019728D1 DE 602005019728 D1 DE602005019728 D1 DE 602005019728D1 DE 602005019728 T DE602005019728 T DE 602005019728T DE 602005019728 T DE602005019728 T DE 602005019728T DE 602005019728 D1 DE602005019728 D1 DE 602005019728D1
Authority
DE
Germany
Prior art keywords
myeloid
chlorotoxine
diagnosis
derivative
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005019728T
Other languages
English (en)
Inventor
Vernon L Alvarez
Matthew A Gonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmolecular Inc
Original Assignee
Transmolecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmolecular Inc filed Critical Transmolecular Inc
Publication of DE602005019728D1 publication Critical patent/DE602005019728D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
DE602005019728T 2004-04-06 2005-04-06 Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat Active DE602005019728D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55943304P 2004-04-06 2004-04-06
PCT/US2005/011523 WO2005099774A2 (en) 2004-04-06 2005-04-06 Diagnosis and treatment of myeloid and lymphoid cell cancers

Publications (1)

Publication Number Publication Date
DE602005019728D1 true DE602005019728D1 (de) 2010-04-15

Family

ID=35150508

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005019728T Active DE602005019728D1 (de) 2004-04-06 2005-04-06 Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat

Country Status (9)

Country Link
US (1) US20110311445A1 (de)
EP (1) EP1756270B1 (de)
JP (2) JP2007532879A (de)
AT (1) ATE459642T1 (de)
AU (1) AU2005232616A1 (de)
CA (1) CA2561494A1 (de)
DE (1) DE602005019728D1 (de)
ES (1) ES2339683T3 (de)
WO (1) WO2005099774A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
WO2009140599A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
EP2531206B1 (de) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxinpolypeptide sowie konjugate und verwendungen davon
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
RU2473901C1 (ru) * 2012-02-22 2013-01-27 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ быстрой диагностики перевиваемого пролимфоцитарного лейкоза у мышей линии akr/jy
BR112015013515A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CA2988504A1 (en) * 2014-07-02 2016-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas
JP7080478B2 (ja) * 2017-09-14 2022-06-06 株式会社西部技研 ガス置換用ドライルーム
WO2019055840A1 (en) 2017-09-15 2019-03-21 Eisai Inc. CHLOROTOXIN AGENTS AND USES THEREOF
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345959A1 (en) * 2001-06-26 2003-01-08 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
JP2005537234A (ja) * 2002-05-31 2005-12-08 トランスモルキュラー インコーポレイテッド クロロトキシンとの併用化学療法
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
JP2007532879A (ja) 2007-11-15
EP1756270A4 (de) 2007-10-24
WO2005099774A2 (en) 2005-10-27
ES2339683T3 (es) 2010-05-24
CA2561494A1 (en) 2005-10-27
EP1756270B1 (de) 2010-03-03
EP1756270A2 (de) 2007-02-28
ATE459642T1 (de) 2010-03-15
AU2005232616A1 (en) 2005-10-27
US20110311445A1 (en) 2011-12-22
JP2011149961A (ja) 2011-08-04
WO2005099774A3 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
ATE459642T1 (de) Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
GEP20196963B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
DE602006010776D1 (de) Piperazinylalkylpyrazol-Derivate zur Verwendung als selektive Calciumkanalblocker des T-Typs und Verfahren zu ihrer Herstellung
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
SG162753A1 (en) Methods of treating cancer and other conditions or disease states using lfmau and ldt
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
NO20072290L (no) Organiske forbindelser.
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
ATE452134T1 (de) Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
Mohite et al. Differential trend of leprosy in rural and urban area of Western Maharashtra
DE10390950D2 (de) Vorrichtung zur Behandlung von Patienten mittels Hirnstimulation
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
ATE421517T1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition